Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. Am J Hematol. 2016 08; 91(8):800-5.